Antibe Therapeutics Inc.
ATBPFOTCHealthcare
$0.22
$-0.00(-0.19%)
Market Cap$11428827
P/E Ratio—
52W High$0.216
52W Low$0.1889
Antibe Therapeutics Inc. (ATBPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATBPF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Feb 14, 2024EPS Actual
-$0.06
Est. -$0.09 · +33.3%
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Feb 14, 2024
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
ATBPF reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2024 | Nov 11, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Aug 12, 2024 | -$0.06 | — | — | — | — | — |
| ◌ Q2 FY2024 | Jun 27, 2024 | -$0.07 | — | — | — | — | — |
| ▲ Q1 FY2024 | Feb 14, 2024 | -$0.09 | -$0.06 | +33.3% | — | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | -$0.09 | -$0.07 | +22.2% | — | — | — |
| — Q3 FY2023 | Aug 14, 2023 | -$0.08 | -$0.08 | +0.0% | — | — | — |
| — Q1 FY2023 | Mar 31, 2023 | — | -$0.05 | — | — | — | — |
| ▲ Q1 FY2023 | Feb 14, 2023 | -$0.09 | -$0.06 | +33.3% | — | — | — |
Q4 FY2024
Nov 11, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 12, 2024
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 27, 2024
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 14, 2024Beat
EPS Actual
-$0.06
EPS Est.
-$0.09
EPS Surpr.
+33.3%
Revenue
—
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
—
Q3 FY2023
Aug 14, 2023
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2023
Mar 31, 2023
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Feb 14, 2023Beat
EPS Actual
-$0.06
EPS Est.
-$0.09
EPS Surpr.
+33.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q4 FY2024 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2024 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q2 FY2024 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2024 | Feb 14, 2024 | +33.3% | $0.67 | $0.68 | +0.81% |
| ▲ Q4 FY2023 | Nov 13, 2023 | +22.2% | $0.70 | $0.66 | -5.19% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +0.0% | $0.42 | $0.41 | -1.26% |
| — Q1 FY2023 | Mar 31, 2023 | — | $0.46 | $0.44 | -3.45% |
| ▲ Q1 FY2023 | Feb 14, 2023 | +33.3% | $0.45 | $0.43 | -4.18% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +25.0% | $0.37 | $0.36 | -1.53% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +11.1% | $0.50 | $0.50 | +0.74% |
| — Q1 FY2022 | Mar 31, 2022 | — | $0.62 | $0.64 | +2.21% |
Q1 FY2024+0.81%
Report Date
Feb 14, 2024
EPS Beat/Miss
+33.3%
Price Before
$0.67
Price After
$0.68
Q4 FY2023-5.19%
Report Date
Nov 13, 2023
EPS Beat/Miss
+22.2%
Price Before
$0.70
Price After
$0.66
Q3 FY2023-1.26%
Report Date
Aug 14, 2023
EPS Beat/Miss
+0.0%
Price Before
$0.42
Price After
$0.41
Q1 FY2023-3.45%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$0.46
Price After
$0.44
Q1 FY2023-4.18%
Report Date
Feb 14, 2023
EPS Beat/Miss
+33.3%
Price Before
$0.45
Price After
$0.43
Q4 FY2022-1.53%
Report Date
Nov 14, 2022
EPS Beat/Miss
+25.0%
Price Before
$0.37
Price After
$0.36
Q3 FY2022+0.74%
Report Date
Aug 15, 2022
EPS Beat/Miss
+11.1%
Price Before
$0.50
Price After
$0.50
Q1 FY2022+2.21%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$0.62
Price After
$0.64
Avg Beat Reaction-1.77%
Beat Rate6 / 8 quarters
Largest Move-5.19% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATBPF ends December
Antibe Therapeutics Inc. (ATBPF) most recently reported earnings on February 14, 2024 for Q1 FY2024, posting EPS of $-0.06 — beating the analyst consensus of $-0.09 by +33.3%. ATBPF has beaten EPS estimates for 7 consecutive quarters. The next ATBPF earnings date is expected around September 1, 2026.
Each quarter, investors track ATBPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATBPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATBPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATBPF earnings · 5 questionsAntibe Therapeutics Inc.'s next earnings report is expected around September 1, 2026. ATBPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATBPF historically reports after market close (AMC).
ATBPF earnings datewhen is ATBPF earningsATBPF next earnings datewhen does ATBPF report earningsATBPF earnings calendar
▸ Source: FMP · Antibe Therapeutics Inc. SEC filings · US GAAP · Antibe Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026